Dr. Jackson on VEGF Versus PARP Inhibitors in Recurrent Ovarian Cancer
Amanda L. Jackson, MD, discusses choosing between VEGF inhibitors and PARP inhibitors in the treatment of patients with recurrent platinum-sensitive ovarian cancer.
Dr Phillips on the Treatment Landscape for Patients With MCL
Dr Chari on the Bridging the Gaps in Hematologic Malignancies Meeting
Dr Danilov on Addressing Unmet Needs in Hematologic Malignancies
Dr Saeed on the Use of Pola-R-CHP in Previously Untreated DLBCL
2 Commerce Drive Cranbury, NJ 08512